ALKERMES | ALKS - Gross Profit On Sales


ALKERMES reported $265.83M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Acadia Pharmaceuticals USD 256.99M 13.15M Sep/2025
ALKERMES USD 265.83M 8.06M Sep/2025
Amgen USD 6.48B 307M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Coherus Biosciences USD 4.95M 15.34M Mar/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Gilead Sciences USD 6.31B 106M Dec/2025
Heron Therapeutics USD 23.35M 1.6M Sep/2024
Ionis Pharmaceuticals USD 155M 293M Sep/2025
J&J USD 16.6B 118M Dec/2025
Merck USD 13.42B 431M Sep/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Nektar Therapeutics USD 13.75M 650K Jun/2024
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Otsuka Holdings JPY 457.41B 28.26B Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025